Leuprolide (leuprorelin) and GnRH agonists

Medicare

Part B (clinician-administered)

Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. Depot injections given in the clinic (HCPCS J9217 for leuprolide 7.5 mg) are Part B. Self-administered forms are rare in oncology.

Commercial insurance

covered on label

Covered under the medical benefit; plans may prefer one depot brand (Lupron Depot, Eligard, Camcevi) over another.

20% Part B coinsurance on a high-cost infusion adds up quickly: Medigap Plan G or N, Medicare Advantage maximum out-of-pocket, Medicaid dual eligibility, or a charity fund are the usual buffers.

Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.

Notes

Generic and biosimilar GnRH agonists (leuprorelin, goserelin, triptorelin) are the backbone of NHS androgen deprivation; funded routinely without a TA.

NHS England

Routinely funded for the appraised indication (or via managed access)

Sources: NICE search: leuprorelin and GnRH agonists. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.